Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
asciminib + blinatumomab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Scemblix + blinatumomab is an investigational chemotherapy-free combination regimen pairing the approved small-molecule kinase inhibitor asciminib (Scemblix) with the bispecific T-cell engager (BiTE) antibody construct blinatumomab (Blincyto). Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that binds allosterically to the myristoyl pocket of ABL1, inducing an inactive conformation of the BCR-ABL1 fusion protein. Blinatumomab is a bispecific monoclonal antibody designed to direct T-cell-mediated cytotoxicity against CD19-positive B-lineage cells by simultaneously binding CD19 on B cells and CD3ε on T cells. This combination is being evaluated in a Phase I/II clinical trial (NCT06308588) for the treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and lymphoid blast phase chronic myeloid leukemia (CML).
- Other names
- Scemblix + BlincytoScemblix + blinatumomabasciminib + Blincytoblinatumomab + Scemblixblinatumomab + asciminib
02
Targets
CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)
Beyond the preview
Go deeper on asciminib + blinatumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on asciminib + blinatumomab.